Date: 2014-07-07
Type of information: Milestone
Compound: antibodies from BioInvent\'s n-CoDeR® libraries
Company: Bioinvent (Sweden) Bayer (Germany)
Therapeutic area:
Type agreement: R&D
Action mechanism: The n-CoDeR® libraries contain more than 20 billion highly diverse, fully human antibody fragments that have been created using BioInvent\'s patented approach, generating antibodies with high affinity and selectivity. Complementarity Determining Regions (CDRs), which defines the antigen binding specificity were originally isolated from the antibodies of a large number of healthy volunteers. Using the n-CoDeR® technology the fully human CDRs are recombined into new antibody molecules. This recombination process allows the library to contain a wider variety of antibodies than could have been created naturally by the human immune system. Two library formats exist, one containing the smaller scFv antibody fragment and the other containing the Fab antibody fragment. Antibodies from the library are selected using an established technology called phage display. Selected targets are used as bait to fish out those antibodies that bind to the target. As n-CoDeR® is an in vitro system, the bait can take any format including cells, proteins or peptides. The relevant antibody genes can then be produced within the bacteria, E. coli.
Disease:
Details: * On October 14, 2013, BioInvent International has announced that it has signed an extension to its 2008 license agreement with Bayer Pharma AG for the development of antibodies from BioInvent\'s n-CoDeR® libraries. Under the terms of the extension, Bayer will broaden its access to BioInvent\'s discovery and development technology platform.
-
Financial terms: BioInvent will receive an undisclosed license fee to cover new projects plus success-based milestone payments and royalties on products already in development.
Latest news: * On July 7, 2014, BioInvent International announced that it has received two separate milestone payments, together worth € 1 million, as a result of milestones being reached under collaborations with Bayer Pharma and Servier. The milestone payment from Bayer was paid as the first patient was enrolled in a phase I clinical trial of an antibody identified from BioInvent’s n-CoDeR® library. Specific milestone payments were not disclosed.
